BARBARA ANN KARMANOS CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1995-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.karmanos.org
Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT00068653
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Chemotherapy in Treating Patients With Advanced Kidney Cancer
- Conditions
- First Posted Date
- 2003-08-08
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00011973
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
- Conditions
- First Posted Date
- 2003-08-08
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00005027
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00066326
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Combination Chemotherapy In Treating Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2003-05-02
- Last Posted Date
- 2013-04-08
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 36
- Registration Number
- NCT00003925
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia
- Conditions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 38
- Registration Number
- NCT00056004
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT00030407
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00016185
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT00004024
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 36
- Registration Number
- NCT00004144
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States